Home > Search Clinical Trials > All > Trial Details

Clinical Trial Details
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of BMS-931699 vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects with Active Systemic Lupus Erythematosus
Clinical Trial ( IRB ) #: 15-102-3
Title: A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of BMS-931699 vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects with Active Systemic Lupus Erythematosus
Principal Investigator: Dr. Santhanan Lakshminarayanan
Description: The purpose of this study is to evaluate the safety, tolerability and effectiveness of a new investigational drug (BMS-931699) that is being studied in male and female patients with Active Systemic Lupus Erythematosus (SLE).
Classification:
  Infectious Disease/Immune System (HIV/AIDS, Hepatitis)
Eligibility Criteria: Check with study contact
How to Contact: Kim Striegel. Telephone: 860-679-2589. Email: kstriegel@uchc.edu or Marie Breen. Telephone: Not available. Email: Not available
Enrollment Status/Comments: Enrolling/recruiting. For current recruitment status, please check with study contact.